EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pyxis Oncology's enterprise value is $-11.25 Mil.
Pyxis Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-83.39 Mil. Therefore, Pyxis Oncology's EV-to-EBITDA for today is 0.13.
The historical rank and industry rank for Pyxis Oncology's EV-to-EBITDA or its related term are showing as below:
PYXS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.25 Med: -0.74 Max: 0.78
Current: 0.13
During the past 6 years, the highest EV-to-EBITDA of Pyxis Oncology was 0.78. The lowest was -2.25. And the median was -0.74.
PYXS's EV-to-EBITDA is ranked better than 88.82% of 501
companies
in the Biotechnology industry
Industry Median: 7.89
vs PYXS: 0.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Pyxis Oncology EV-to-EBITDA Historical Data
The historical data trend for Pyxis Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pyxis Oncology's EV-to-EBITDA
For the Biotechnology subindustry, Pyxis Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's EV-to-EBITDA falls into.
Pyxis Oncology's current Enterprise Value is $-11.25 Mil.
Pyxis Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-83.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pyxis Oncology's PE Ratio (TTM) for today is calculated as:
Pyxis Oncology's share price for today is $1.23.
Pyxis Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Pyxis Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PYXS has been successfully added to your 